We are live on
!
Find out more
DTC
Deep Track Capital Portfolio holdings
AUM
$6.87B
1-Year Est. Return
205.24%
This Fund
S&P 500
This Quarter
Est. Return
+25.88%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.99B
AUM Growth
+$404M
(+16%)
Cap. Flow
-$138M
Cap. Flow
% of AUM
-4.62%
Top 10 Holdings %
Top 10 Hldgs %
40.51%
Holding
78
New
15
Increased
15
Reduced
16
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$140M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$48M |
| 3 |
ABVX
Abivax
ABVX
|
+$43.8M |
| 4 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$42.2M |
| 5 |
TRML
Tourmaline Bio
TRML
|
+$36.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$136M |
| 2 |
Structure Therapeutics
GPCR
|
+$92.6M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$75.9M |
| 4 |
Immunovant
IMVT
|
+$66.2M |
| 5 |
NovoCure
NVCR
|
+$40.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.33% |
| 2 | Miscellaneous | 4.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$27B
| $166M | 5.54% |
5,350,000
-650,000
| -11% | -$16.9M |
|
|
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
| $148M | 4.95% |
4,063,676
+517,241
| +15% | +$13.5M |
|
|
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $143M | 4.78% |
2,000,000
-600,000
| -23% | -$34.5M |
|
4
Guardant Health
GH
$23.7B
| $135M | 4.52% |
5,000,000
+950,000
| +23% | +$24.9M |
|
|
5
argenx
ARGX
$61.4B
| $114M | 3.81% |
+300,000
| New | +$140M |
|
6
CALL
Cytokinetics
CYTK
$9.75B
| $112M | 3.76% |
+1,347,300
| New | +$48.8M |
|
7
Alkermes
ALKS
$7.74B
| $111M | 3.71% |
4,000,000
+200,000
| +5% | +$5.2M |
|
8
Pliant Therapeutics
PLRX
$70M
| $104M | 3.48% |
5,750,000
+250,000
| +5% | +$3.8M |
|
|
DVAX
9
DELISTED
Dynavax Technologies
DVAX
| $99.2M | 3.31% |
7,093,214
+336,258
| +5% | +$4.67M |
|
10
Axsome Therapeutics
AXSM
$11.1B
| $79.6M | 2.66% |
1,000,000
-140,745
| -12% | -$9.41M |
|
11
Viridian Therapeutics
VRDN
$2.47B
| $79.1M | 2.64% |
3,631,728
+668,461
| +23% | +$10.6M |
|
|
AUTL
12
Autolus Therapeutics
AUTL
$503M
| $76.4M | 2.55% |
11,869,297
-3,130,703
| -21% | -$11.9M |
|
13
Pacific Biosciences
PACB
$420M
| $68.7M | 2.29% |
7,000,000
+1,000,000
| +17% | +$8.18M |
|
14
Intellia Therapeutics
NTLA
$1.62B
| $68.6M | 2.29% |
2,250,000
+250,000
| +13% | +$7.18M |
|
15
Travere Therapeutics
TVTX
$5.99B
| $66.3M | 2.21% |
7,370,000
| – | – |
|
|
APGE
16
DELISTED
Apogee Therapeutics
APGE
| $64.9M | 2.17% |
2,323,456
-90,917
| -4% | -$1.82M |
|
|
VRNA
17
DELISTED
Verona Pharma
VRNA
| $63.4M | 2.12% |
3,187,415
| – | – |
|
|
18
Ionis Pharmaceuticals
IONS
$7.55B
| $63.2M | 2.11% |
1,249,068
-1,585,001
| -56% | -$75.9M |
|
|
BCYC
19
Bicycle Therapeutics
BCYC
$255M
| $63.1M | 2.11% |
3,490,506
| – | – |
|
20
Geron
GERN
$835M
| $62.4M | 2.08% |
29,583,449
+3,883,449
| +15% | +$7.55M |
|
21
Editas Medicine
EDIT
$416M
| $55.4M | 1.85% |
5,473,086
-1,628,849
| -23% | -$14.3M |
|
|
AMAM
22
DELISTED
Ambrx Biopharma Inc
AMAM
| $52.8M | 1.76% |
+3,710,412
| New | +$42.2M |
|
|
23
Sarepta Therapeutics
SRPT
$2.12B
| $48.2M | 1.61% |
+500,000
| New | +$48M |
|
|
TRML
24
DELISTED
Tourmaline Bio
TRML
| $47.5M | 1.59% |
+1,815,854
| New | +$36.3M |
|
|
HLVX
25
DELISTED
HilleVax
HLVX
| $46.5M | 1.55% |
2,900,000
| – | – |
|
Similar funds
PFS
EWM
NP
NPT
RCWMU
CA
LIP
CI
Deep Track Capital's Q4 2023 Portfolio in Review
As of Q4 2023, Deep Track Capital held 78 positions worth $2.99B, up 16% from $2.59B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Deep Track Capital withdrew a net $138M in Q4 2023, closing 18 positions and reducing 16 holdings. Its most notable exit was NovoCure, an estimated $40.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Deep Track Capital opened a new position in argenx worth $114M.
- Deep Track Capital's largest Q4 2023 buy was argenx: 300,000 shares worth $114M.
- Deep Track Capital added most to Guardant Health in Q4 2023, an estimated $24.9M increase.
- Deep Track Capital's biggest Q4 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $136M.
- Deep Track Capital fully exited NovoCure in Q4 2023, selling an estimated $40.4M.
- Deep Track Capital's ten largest holdings make up 41% of its $2.99B portfolio in Q4 2023.
- Deep Track Capital opened 15 new positions and closed 18 in Q4 2023.
- Deep Track Capital's portfolio value rose 16% quarter-over-quarter to $2.99B.
Based on Deep Track Capital's 13F filing for Q4 2023, filed 14 Feb 2024.